Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

Withdrawn before enrolling · Phase 1

Conditions studied: Focal Segmental Glomerulosclerosis

In brief

This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant FSGS.

Key facts

Study ID

NCT00816504

Run by

Northwell Health

People needed

0

Starts

2008-12-01

Expected to finish

2009-12-01

Last updated by the study team

2015-09-07

Who can join

Age: 2 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary FSGS
• CKD Stage 5
• Resistance to steroids and another immunosuppressive medication

You may not qualify if…

• Secondary FSGS

Where it is running

• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.